The Gates Foundation will invest up to $50 million to support Tessera's SCD gene editing treatment, the company said.

More than 500,000 babies were tested for sickle cell disease in Catalonia’s newborn screening program, with 160 cases ...

Gene-editing kicked off 2024 with a bang in the medical sector but closed the year with a whimper. It started with the FDA ...

A phase 3 trial highlights betibeglogene autotemcel as a potentially curative gene therapy for severe transfusion-dependent β ...

Researchers developed a novel calculator may help to tailor pain medication regimens to patients with SCD seeking emergency ...

The following is a summary of “Safety and efficacy of mitapivat in sickle cell disease (RISE UP): results from the phase 2 ...